Jaguar Health Q4 2025 Earnings Report and Out-License Agreement with Future Pak
Jaguar Health (NASDAQ: JAGX) reported a net revenue of $3.2 million for the fourth quarter, showing sequential growth but an eight percent decline year-over-year. The company closed an out-license agreement with Future Pak for Mytesi and Canalevia-CA1, receiving upfront payments totaling nearly $4 million plus potential future milestones worth up to $20 million.
Topics: clinical_data loss_from_operations out-license_agreement revenue